<DOC>
	<DOC>NCT02243813</DOC>
	<brief_summary>The current protocol is a pilot study of the effects and possible utility of psilocybin-facilitated experiences for professional religious leaders.</brief_summary>
	<brief_title>Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion</brief_title>
	<detailed_description />
	<mesh_term>Psilocybine</mesh_term>
	<criteria>Inclusion criteria: Have given written informed consent College graduation or equivalent and graduate/professional training. Recognized leadership position in a wellestablished religious organization; professional activities must include significant time interacting with those seeking religious/spiritual guidance or support. Be healthy and psychologically stable as determined by screening for medical and psychiatric problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests During the next year there is no foreseen likelihood for a major potentially lifealtering event for her or himself or a close family member (e.g. retirement or major career change for the volunteer; lifethreatening illness of a spouse or child of the volunteer) Agree to consume approximately the same amount of caffeinecontaining beverage (e.g., coffee, tea) that he/she consumes on a usual morning, before arriving at the research unit on the mornings of psilocybin session days. If the participant does not routinely consume caffeinated beverages, he/she must agree not to do so on session days. Agree to refrain from using any psychoactive drugs, including alcoholic beverages and nicotine, 24 hours before and after each drug administration. The exception is caffeine. Participants will be required to be either a nonsmoker or a nondaily smoker. Agree not to take any PRN medications on the mornings of drug sessions Agree not to take sildenafil (ViagraÂ®), tadalafil, or similar medications within 72 hours of each drug administration. Agree that for one week before each drug session, he/she will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the study investigators. Exceptions will be evaluated by the study investigators and will include acetaminophen, nonsteroidal antiinflammatory drugs, and common doses of vitamins and minerals. General medical exclusion criteria: Women who are pregnant (as indicated by a positive urine pregnancy test assessed at intake and before each drug session) or nursing; women who are of childbearing potential and sexually active who are not practicing an effective means of birth control. Cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled hypertension, a clinically significant ECG abnormality (e.g., symptomatic atrial fibrilation), or TIA in the past year Epilepsy with history of seizures Insulindependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia Currently taking psychoactive prescription medication on a regular (e.g., daily) basis Currently taking on a regular (e.g., daily) basis any medications having a primary centrallyacting pharmacological effect on serotonin neurons or medications that are MAO inhibitors. For individuals who have intermittent or PRN use of such medications, psilocybin sessions will not be conducted until at least 5 halflives of the agent have elapsed after the last dose. More than 20% outside the upper or lower range of ideal body weight according to Metropolitan Life height and weight table Psychiatric Current or past history of meeting DSM5 criteria for Schizophrenia, Psychotic Disorder (unless substanceinduced or due to a medical condition), or Bipolar I or II Disorder Current or past history within the last 5 years of meeting DSM5 criteria for alcohol or substance use disorder (excluding caffeine and nicotine) or severe major depression Have a first or seconddegree relative with Schizophrenia, Psychotic Disorder (unless substance induced or due to a medical condition), or Bipolar I or II Disorder Has a psychiatric condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Psilocybin</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Psychotropic Drugs</keyword>
</DOC>